Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A meta-analysis of randomized controlled trials

JAMA

Volumn 293, Issue 21, 2005, Pages 2641-2647

  Andraws, Richard ^a   Berger, Jeffrey S ^a   Brown, David L ^b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIINFECTIVE AGENT; ATORVASTATIN; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GATIFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PRAVASTATIN; ROXITHROMYCIN;

CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS; BACTERIAL INFECTION; CORONARY ARTERY ATHEROSCLEROSIS; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANGINA, UNSTABLE; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 19644362702     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.21.2641     Document Type: Review

References (44)

1. Saikku P, Leinonen M, Mattila K, et al. Serologic evidence of an association of a novel Chlamydia TWAR with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-985.
2. Zhu J, Nieto J, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103:45-51.
3. Grahame-Clarke C, Chan NN, Andrew D, et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation. 2003;108:678-683.
4. Li L, Messas E, Batista EL Jr. et al. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation. 2002:105:861-867.
5. Alber DG, Powell KL, Vallance P, et al. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation. 2000;102:779-785.
6. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.
7. Saikku P. Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more. J Infect Dis. 2000;181 (suppl 3):S411-S413.
8. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation. 1997;96:4095-4103.
9. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in atherosclerotic tissue. J Infect Dis. 2000;181 (suppl 3):S437-S440.
10. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischernic heart disease. Circulation. 1999; 99:1555-1559.
11. Sander D, Winbeck K, Klingelhöfer J, et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002;106:2428-2433.
12. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002; 105:1298-1303.
13. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
14. Kalayoglu MV, Indrawati RP, Morrison SG, et al. Chlamydia virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis. 2000;181 (suppl 3):S483-S489.
15. Moazed TC, Kuo C, Grayston JT, et al. Evidence of dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis. 2000;181 (suppl 3):S1322-S1325.
16. Summersgill JT, Molestina RE, Miller RD, et al. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis. 2000;181 (suppl 3):S479-5482.
17. Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation. 1998;98:300-307.
18. Kol A, Bourcier T, Lichtman AH, et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest. 1999;103:571-577.
19. Jackson LA, Grayston JT. Chlamydia pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone Inc; 2000:2007-2014.
20. Ianaro A, Ialenti A, Maffia P, et al. Antiinflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 1999;292:156-163.
21. Martin D, Bursill J, Breit SN, et al. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet. 1998;351:1858-1859.
22. Maitra SR, Bhaduri S, Valane PD, et al. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock. 2003;20:280-285.
23. Higgins JP. Chlamydia pneumoniae and coronary artery disease. Mayo Clin Proc. 2003;78:321-332.
24. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127:531-537.
25. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodologic quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
26. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
27. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized Secondary Prevention Trial of Azithromycin in Patients with Coronary Artery Disease: primary clinical results of the ACADEMIC Study. Circulation. 2000; 102:1755-1760.
28. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study, a randomized controlled trial. JAMA. 2003;290:1459-1466.
29. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J. 1999;20:121-127.
30. Sinisalo J, Mattila K, Valtonen V, et al; Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002; 105:1555-1560.
31. Leowattana W, Bhuripanyo K, Singhaviranon L, et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai. 2001;84(suppl 3):S669-S675.
32. Stone AFM, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219-1223.
33. Zahn R, Schneider S, Frilling B, et al. Antibiotic Therapy After Acute Myocardial Infarction (ANTIBIO): a prospective randomized trial. Circulation. 2003; 107:1253-1259.
34. Cercek B, Shah PK, Noc M, et al. Effect of shortterm treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial. Lancet. 2003;361:809-813.
35. Grayston JT, Kronmal R, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645.
36. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-1654
37. Braunwald E. Cardiovascular medicine at the turn of the millennium. N Engl J Med. 1997;337:1360-1369.
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999:340:115-126.
39. Tousoulis D, Davies G, Stefanadis C, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89:993-997.
40. Forrester JS. Prevention of plaque rupture. Ann Intern Med. 2002;137:823-833.
41. Shimoyama T, Crabtree JE. Bacterial factors and immune pathogenesis in Helicobacter pylori infection. Gut. 1998;43(suppl 1):2S-5S.
42. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species with the coronary arteries of patients with symptomatic atherosclerotic vs other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-1561.
43. Kalayoglu MV, Libby P, Byrne GL. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA, 2002;288:2724-2731.
44. Meier CR. Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis. 2000;181 (suppl3):S558-S562.